Tech Company Financing Transactions
Prota Therapeutics Funding Round
SPRIM Global Investments and private investors joined a $21 million venture round for Prota Therapeutics. The round closed on 1/17/2024.
Transaction Overview
Company Name
Announced On
1/17/2024
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$21,000,000
Round
Undisclosed
Investors
SPRIM Global Investments (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its Phase 3 clinical investigation of PRT120 oral therapy for peanut allergy.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
c/o FB Rice Reception Level 33, 477 Collins Street
Melbourne Vic, 3000
Australia
Melbourne Vic, 3000
Australia
Phone
Undisclosed
Website
Email Address
Overview
Established in 2016, Prota Therapeutics is an Australian biotech company dedicated to developing and commercializing cutting-edge oral immunotherapy treatments. Our focus centers on leveraging proprietary food immunotherapy technology, developed under the leadership of Professor Mimi Tang's research team, and exclusively licensed from the Murdoch Children's Research Institute in Melbourne, Australia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mimi Tang
Chief Financial Officer
Cameron Jones
Browse more venture capital transactions:
Prev: 1/17/2024: Lightship venture capital transaction
Next: 1/17/2024: Prismatic Software venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs